Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5AP | P20292 | 1/20 | 0.41 |
| ▸ | FEN1 | P39748 | 1/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 15/20 | 0.41 |
| ▸ | FAAH | O00519 | 1/20 | 0.40 |
| ▸ | CSF1R | P07333 | 1/20 | 0.39 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4115736 | 0.90 | ACHE (0.40) | — | |
| SCHEMBL4126281 | 0.87 | CSF1R (0.42) | ALOX5APFEN1GPR119FAAHCSF1R | |
| Dimethylamine SCHEMBL4112269 | 0.86 | ALOX5AP (0.42) | ALOX5APFEN1GPR119FAAHCSF1R | |
| SCHEMBL13596403 | 0.86 | ALOX5AP (0.43) | ALOX5APFEN1GPR119FAAHCSF1R | |
| SCHEMBL4122064 | 0.84 | ALOX5AP (0.41) | ALOX5APFEN1GPR119FAAHCSF1R | |
| SCHEMBL4121761 | 0.84 | ALOX5AP (0.41) | ALOX5APFEN1GPR119FAAHCSF1R | |
| SCHEMBL4121756 | 0.84 | ALOX5AP (0.41) | ALOX5APFEN1GPR119FAAHCSF1R | |
| Dimethylamine SCHEMBL4126290 | 0.82 | CSF1R (0.45) | ALOX5APFEN1GPR119FAAHCSF1R | |
| SCHEMBL13597347 | 0.82 | GPR119 (0.43) | GPR119FAAH | |
| SCHEMBL4129938 | 0.82 | GPR119 (0.42) | GPR119FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090318690-A1 | Benzisoxazole Compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-12-24 | — | — | US | disclosed |
| US-20090318690-A1 | Benzisoxazole Compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-12-24 | — | — | US | disclosed |
| US-20090318690-A1 | Benzisoxazole Compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-12-24 | — | — | US | disclosed |
| EP-2017275-A1 | BENZISOXAZOLE COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2009-01-21 | — | — | EP | disclosed |
| EP-2017275-A1 | BENZISOXAZOLE COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2009-01-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318690-A1 | Benzisoxazole Compound | NR1I2, NR1I3, NR0B1 | ALOX5AP 4208/4885FEN1 4250/4885GPR119 122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.